CeQur to get funded with $115 million from investors led by Credit Suisse Entrepreneur Capital Ltd. and Endeavour Vision

CeQur, a Lucerne, Switzerland-based producer of devices for a simple insulin-delivery process, announced the completion of a $115 million capital funding round.

The money was raised from investos led by the Switzerland-based Credit Suisse Entrepreneur Capital Ltd. and Endeavour Vision, joined by Tandem Diabetes Care, Inc., Ypsomed Group, Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.

The proceeds will be used for building a business based on the company's product CeQur Simplicity, including a phased commercial launch strategy that includes a limited market release in 2021.

CeQur was founded in 2008 by its CEO James 'Jim' Peterson with a focud on the development and commercialization of insulin delivery systems to improve the management of type 2 diabete.

The company now developed and sells CeQur Simplicity, a simple, three-day, wearable insulin device for discreet, convenient and injection-free bolus dosing. One Simplicity patch holds up to 200 units of rapid-acting insulin administered in two-unit increments and replaces, on average, nine mealtime injections over three days. Clinical research has shown that nearly 90% of patients using CeQur Simplicity reported following their insulin regimen better as compared to multiple daily injections MDI. The device is clinically proven and both FDA cleared and CE-marked.